A randomized trial of selenium supplementation and risk of type-2 diabetes, as assessed by plasma adiponectin

[thumbnail of WRAP_Stranges_journal.pone.0045269.pdf]
Preview
Text
WRAP_Stranges_journal.pone.0045269.pdf - Published Version

Download (547kB) | Preview

Request Changes to record.

Abstract

Background: Evidence that selenium affects the risk of type-2 diabetes is conflicting, with observational studies and a few randomized trials showing both lower and higher risk linked to the level of selenium intake and status. We investigated the effect of selenium supplementation on the risk of type-2 diabetes in a population of relatively low selenium status as part of the UK PRECISE (PREvention of Cancer by Intervention with SElenium) pilot study. Plasma adiponectin concentration, a recognised independent predictor of type-2 diabetes risk and known to be correlated with circulating selenoprotein P, was the biomarker chosen. Methods: In a randomized, double-blind, placebo-controlled trial, five hundred and one elderly volunteers were randomly assigned to a six-month intervention with 100, 200 or 300 μg selenium/d as high-selenium or placebo yeast. Adiponectin concentration was measured by ELISA at baseline and after six months of treatment in 473 participants with one or both plasma samples available. Results: Mean (SD) plasma selenium concentration was 88.5 ng/g (19.1) at baseline and increased significantly in the selenium-treatment groups. In baseline cross-sectional analyses, the fully adjusted geometric mean of plasma adiponectin was 14% lower (95% CI, 0-27%) in the highest than in the lowest quartile of plasma selenium (P for linear trend = 0.04). In analyses across randomized groups, however, selenium supplementation had no effect on adiponectin levels after six months of treatment (P = 0.96). Conclusions: These findings are reassuring as they did not show a diabetogenic effect of a six-month supplementation with selenium in this sample of elderly individuals of relatively low selenium status.

Item Type: Journal Article
Subjects: Q Science > QP Physiology
R Medicine > RC Internal medicine
R Medicine > RM Therapeutics. Pharmacology
Divisions: Faculty of Science, Engineering and Medicine > Medicine > Warwick Medical School > Health Sciences
Faculty of Science, Engineering and Medicine > Medicine > Warwick Medical School
Library of Congress Subject Headings (LCSH): Selenium -- Physiological effect, Non-insulin-dependent diabetes -- Susceptibility
Journal or Publication Title: PLoS One
Publisher: Public Library of Science
ISSN: 1932-6203
Official Date: 2012
Dates:
Date
Event
2012
Published
Volume: Vol.7
Number: No.9
Page Range: e45269
DOI: 10.1371/journal.pone.0045269
Status: Peer Reviewed
Publication Status: Published
Access rights to Published version: Restricted or Subscription Access
Date of first compliant deposit: 22 December 2015
Date of first compliant Open Access: 22 December 2015
Funder: Cancer Research UK (CRUK), University of Surrey, Pharma Nord (Denmark), Deutsche Forschungsgemeinschaft (DFG)
Grant number: STE 1782/2-2 (DFG)
URI: https://wrap.warwick.ac.uk/50176/

Export / Share Citation


Request changes or add full text files to a record

Repository staff actions (login required)

View Item View Item